Truist Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $105-Report released on 8th February 2024
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has maintained a Buy rating on Tenet Healthcare (NYSE:THC) and increased the price target from $92 to $105 as of 8th February 2024.
February 09, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reaffirmed a Buy rating on Tenet Healthcare and raised the price target from $92 to $105.
The upgrade in price target by a reputable analyst like David Macdonald suggests a strong confidence in Tenet Healthcare's future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100